Table I.
Inhaled Combination Formulations for Asthma and COPD that are in Development or Commercially Available
| Active ingredients | Brand | Manufacturer | Product type | Status |
|---|---|---|---|---|
| Fluticasone, Salmeterol | Advair®, Seretide®, Viani®, Adoair® | GlaxoSmithKline | DPI, pMDI | Market |
| Seroflo® | Cipla | |||
| Beclomethasone, Formoterol | Foster®, Formodual®, Innovair® | Chiesi | pMDI | Market |
| Formoterol, Mometasone | Dulera® | Merck | pMDI | Market |
| Budesonide, Formoterol | Symbicort® | AstraZeneca | DPI, pMDI | Market |
| Foracort® | Cipla | DPI, pMDI | Market | |
| Formoterol, Tiotropium | Duova® | Cipla | DPI, pMDI | Market |
| Ipratropium, Salbutamol | Combivent® | Boehringer Ingelheim | Nebulizer, Respimat® | Market |
| Duoneb® | Myan | Nebulizer | Market | |
| Ipramol® | TEVA | DPI, Nebulizer | Market | |
| Duolin® | Cipla | DPI, Nebulizer, pMDI | Market | |
| Beclomethasone, Salbutamol | Aerocort® | Cipla | DPI, pMDI | Market |
| Budesonide, Salbutamol | Budesal® | Cipla | Nebulizer | Market |
| Fenoterol, Ipratropium | Duovent®, Berodual®, Bronchodual®, Atrovent® | Boehringer Ingelheim | Nebulizer, pMDI, Respimat® | Market |
| Ipraterol®, Fenovent® | Cipla | Nebulizer, pMDI | Market | |
| Ciclesonide, Formoterol, Tiotropium | Triohale® | Cipla | pMDI | Market |
| Formoterol, Fluticasone | Flutiform® | SkyePharma | pMDI | Market |
| Fluticasone, Vilanterol | Breo™ | GlaxoSmithKline | DPI | Market |
| Glycopyrrolate, Indacaterol | Ultibro® Breezhaler® | Novartis | DPI | Market |
| Aclidinium, Eformoterol | LAS40464 | Almirall | DPI | Filed |
| GSK573719, Vilanterol | – | GlaxoSmithKline | DPI | Phase III |
| Indacaterol, Mometasone | QMF149 | Novartis | DPI | Phase III |
| Formoterol, Glycopyrrolate | PT003 | Pearl | pMDI | Phase III |
| Olodaterol, Tiotropium | – | Boehringer Ingelheim | Respimat® | Phase III |
Data from (136)